Case Report: Pregnant ROS1+ lung cancer patient treated with crizotinib - Impact on infancy.
증례보고
1/5 보강
Lung cancer remains the leading cause of cancer-related deaths worldwide.
APA
Weber T, Hoffmann J, et al. (2026). Case Report: Pregnant ROS1+ lung cancer patient treated with crizotinib - Impact on infancy.. Frontiers in oncology, 16, 1784859. https://doi.org/10.3389/fonc.2026.1784859
MLA
Weber T, et al.. "Case Report: Pregnant ROS1+ lung cancer patient treated with crizotinib - Impact on infancy.." Frontiers in oncology, vol. 16, 2026, pp. 1784859.
PMID
41883965 ↗
Abstract 한글 요약
Lung cancer remains the leading cause of cancer-related deaths worldwide. Managing cancer treatment during pregnancy is a rare yet challenging condition, with limited data available on maternal and neonatal outcomes. We present the case of a 37-year-old pregnant woman diagnosed with ROS-1-rearranged metastatic NSCLC, who was treated with crizotinib and subsequently delivered a preterm infant. Our report underscores the critical need for rigorous thromboembolic monitoring in pregnant patients undergoing cancer treatment. Furthermore, we provide evidence that placental tissue significantly reduces fetal crizotinib exposure, suggesting that crizotinib might be a viable therapeutic option for maintaining a pregnancy during lung cancer treatment.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Reforming the delivery of smoking cessation: a distributional cost-effectiveness analysis of providing smoking cessation as part of targeted lung cancer screening.
- A herbal formulation inhibits growth and survival of lung cancer cells through DNA damage and apoptosis - in vitro and in vivo studies.
- Negative trial but positive lesson: reframing immunotherapy resistance from one-size-fits-all to precision strategies.
- Lung Cancer Screening in Adults: State-of-the-Art and Policy Mapping (2025).
- Retrospective dosimetric evaluation of the collapsed cone, AAA, and Acuros XB algorithms for lung cancer Halcyon VMAT plans.
- Virtual screening of novel alkaloids as potent inhibitors for G2032R-mutant ROS1 kinase in non-small-cell lung cancer.